Why Miracell’s SMART M-CELL FDA clearance could reshape the PRP and BMAC device market
Miracell has won FDA 510(k) clearance for SMART M-CELL. Read what it changes for PRP, BMAC, adoption, and regenerative medicine competition.
Why InterVene’s first 30 Recana cases could reshape treatment for venous in-stent restenosis
InterVene has completed 30 Recana cases, raising new questions about venous ISR treatment, adoption, and launch strategy. Read the full analysis.
Can VR LIFE and H2 Global Group turn European MedTech validation into real global scale?
Can VR LIFE and H2 Global Group scale from European validation to global MedTech relevance? Read the deeper analysis now.
Can Allevion Medical’s Vantage change spinal stenosis workflows by combining disposable access, illumination, and bone resection tools?
Allevion Medical’s Vantage won FDA 510(k) clearance for lumbar decompression. Read what this may change for spinal stenosis workflow, adoption, and risk.
How ATL Medical’s PREVOYANCE imaging system could speed arthroscopy device development with OMNIVISION’s OH0131 processor
ATL Medical and OMNIVISION have expanded arthroscopy imaging integration. Read what this means for OEM speed, quality, and device development.
LUNA trial 2026: Spark Biomedical tests non-pharmacological device for heavy menstrual bleeding
Spark Biomedical launches LUNA Phase II trial evaluating wearable auricular neurostimulation for heavy menstrual bleeding. What the study design reveals.
Photonova Spectra FDA clearance gives GE HealthCare a stronger hand in advanced CT imaging
GE HealthCare’s Photonova Spectra just won FDA clearance. Find out what this means for photon-counting CT, imaging workflows, and hospital adoption.
Can low-dose radiotherapy reshape osteoarthritis care after Siemens Healthineers’ FDA clearance
Siemens Healthineers expands TrueBeam into osteoarthritis care with FDA clearance. Find out how radiotherapy could reshape chronic pain treatment.
Can Heru’s PretestPro replace multiple pretesting devices in one wearable exam?
Heru’s PretestPro completes four ophthalmic pretests in under two minutes on a VR wearable. Explore what this means for clinic workflow and clinical validation. Read more.
What Neuspera’s 12-month iSNM trial data means for the sacral neuromodulation competitive landscape
Neuspera Medical’s 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.